2023-505135-12-00WithdrawnPhase 1
A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of a pDNA Vaccine Candidate Against COVID-19 in Healthy Adults
Imam Abdulrahman Bin Faisal University1 site in 1 country60 target enrollmentStarted: October 13, 2023Last updated:
Trial Snapshot
- Phase
- Phase 1
- Status
- Withdrawn
- Enrollment
- 60
- Locations
- 1
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Iman Almansour
Scientific
Imam Abdulrahman Bin Faisal University
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 1
Phase IB Study to Assess the Safety, Tolerability and Efficacy of PM14 in combination with Atezolizumab in Pretreated Patients with Selected Advanced Solid Tumors2023-509688-25-00Pharma Mar S.A.50
Recruiting
Phase 1
Study to evaluate the safety, tolerability, maximum tolerated dose and clinical activity of TNB-383B when given to patients with multiple myeloma2023-506993-11-00AbbVie Deutschland GmbH & Co. KG22
Recruiting
Phase 1
A study to assess the safety, tolerability, uptake and efficacy of VMX-C001 in healthy volunteers.2023-507059-32-00VarmX B.V., VarmX B.V.48
Recruiting
Phase 1
A study to evaluate the safety and tolerability of single ascending doses of AGMB-101 in healthy participants (Part A) and patients with liver cirrhosis (Part B).2024-515074-26-00AgomAb Therapeutics64
Active, not recruiting
Phase 1
A Phase 1 Study to evaluate tolerability, safety and efficacy of AB122 and AB154 in Combination with Chemotherapy for Patients With Non-Small Cell Lung CancerJPRN-jRCT2051230009asermoaddeli Ali12